MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.15
+1.11
+4.43%
After Hours: 26.74 +0.59 +2.26% 18:28 09/18 EDT
OPEN
25.49
PREV CLOSE
25.04
HIGH
26.57
LOW
24.60
VOLUME
7.30M
TURNOVER
--
52 WEEK HIGH
27.62
52 WEEK LOW
4.950
MARKET CAP
3.31B
P/E (TTM)
-12.6979
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average TGTX stock price target is 39.29 with a high estimate of 65.00 and a low estimate of 23.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TGTX
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.